Finding New and Better Treatments for Psychiatric Disorders

Overview

Journal Neuropsychopharmacology

Date 2023 Aug 15

PMID 37582978

Authors

Steven M Paul

William Z Potter

Affiliations

Soon will be listed here.

Abstract

In contrast to most fields of medicine, progress to discover and develop new and improved psychiatric drugs has been slow and disappointing. The vast majority of currently prescribed drugs to treat schizophrenia, mood and anxiety disorders are arguably no more effective than the first generation of psychiatric drugs introduced well over 50 years ago. With only a few exceptions current psychiatric drugs work via the same fundamental mechanisms of action as first-generation agents. Here we describe the reasons for this slow progress and outline a number of areas of research that involve a greater reliance on experimental therapeutics utilizing recent advances in neuroscience to better understand disease biology. We exemplify the potential impact of these areas of research focus with several recent examples of novel agents that have emerged and which support our optimism that newer, more effective and better tolerated agents, are on the horizon. Together with existing drugs these newer agents and novel mechanisms could offer markedly improved functional outcomes for the millions of people still disabled by psychiatric disorders.

Citing Articles

Histone monoaminylation is a novel epigenetic mechanism in psychiatric disorders.

Peedicayil J, Santhosh S Front Mol Neurosci. 2025; 18:1534569.

PMID: 40041043 PMC: 11876413. DOI: 10.3389/fnmol.2025.1534569.

GPCR drug discovery: new agents, targets and indications.

Lorente J, Sokolov A, Ferguson G, Schioth H, Hauser A, Gloriam D Nat Rev Drug Discov. 2025; .

PMID: 40033110 DOI: 10.1038/s41573-025-01139-y.

Progesterone Promotes Anti-Anxiety/Depressant-like Behavior and Trophic Actions of BDNF in the Hippocampus of Female Nuclear Progesterone Receptor, but Not 5α-Reductase, Knockout Mice.

Frye C, Cleveland D, Sadarangani A, Torgersen J Int J Mol Sci. 2025; 26(3).

PMID: 39940941 PMC: 11818940. DOI: 10.3390/ijms26031173.

Neuron-Specific Glycine Metabolism Links Transfer RNA Epitranscriptomic Regulation to Complex Behaviors.

Blaze J, Evans V, Feria Pliego J, Unichenko P, Javidfar B, Heissel S Biol Psychiatry Glob Open Sci. 2025; 5(2):100432.

PMID: 39911537 PMC: 11794161. DOI: 10.1016/j.bpsgos.2024.100432.

Classification of schizophrenia, bipolar disorder and major depressive disorder with comorbid traits and deep learning algorithms.

Chen X, Lu Y, Cue J, Han M, Nimgaonkar V, Weinberger D Schizophrenia (Heidelb). 2025; 11(1):14.

PMID: 39910091 PMC: 11799204. DOI: 10.1038/s41537-025-00564-7.

References

Hornykiewicz O . Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord. 2002; 17(3):501-8. DOI: 10.1002/mds.10115. View

Grabb M, Potter W . Central Nervous System Trial Failures: Using the Fragile X Syndrome-mGluR5 Drug Target to Highlight the Complexities of Translating Preclinical Discoveries Into Human Trials. J Clin Psychopharmacol. 2022; 42(3):234-237. PMC: 9060375. DOI: 10.1097/JCP.0000000000001553. View

Trubetskoy V, Pardinas A, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli T . Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022; 604(7906):502-508. PMC: 9392466. DOI: 10.1038/s41586-022-04434-5. View

Singh T, Poterba T, Curtis D, Akil H, Eissa M, Barchas J . Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature. 2022; 604(7906):509-516. PMC: 9805802. DOI: 10.1038/s41586-022-04556-w. View

Iorio-Morin C, Sarica C, Elias G, Harmsen I, Hodaie M . Neuroimaging of psychiatric disorders. Prog Brain Res. 2022; 270(1):149-169. DOI: 10.1016/bs.pbr.2021.12.001. View

Nestler E, Hyman S . Animal models of neuropsychiatric disorders. Nat Neurosci. 2010; 13(10):1161-9. PMC: 3750731. DOI: 10.1038/nn.2647. View

Leucht S, Chaimani A, Mavridis D, Leucht C, Huhn M, Helfer B . Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis. Neuropsychopharmacology. 2019; 44(11):1955-1966. PMC: 6785090. DOI: 10.1038/s41386-019-0440-6. View

Mott M, Gordon J, Koroshetz W . The NIH BRAIN Initiative: Advancing neurotechnologies, integrating disciplines. PLoS Biol. 2018; 16(11):e3000066. PMC: 6283590. DOI: 10.1371/journal.pbio.3000066. View

Latimer C, Lucot K, Keene C, Cholerton B, Montine T . Genetic Insights into Alzheimer's Disease. Annu Rev Pathol. 2021; 16:351-376. PMC: 8664069. DOI: 10.1146/annurev-pathmechdis-012419-032551. View

10.

Veitch D, Weiner M, Aisen P, Beckett L, DeCarli C, Green R . Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease. Alzheimers Dement. 2021; 18(4):824-857. PMC: 9158456. DOI: 10.1002/alz.12422. View

11.

Tang K, Antshel K, Fremont W, Kates W . Behavioral and Psychiatric Phenotypes in 22q11.2 Deletion Syndrome. J Dev Behav Pediatr. 2015; 36(8):639-50. PMC: 4586411. DOI: 10.1097/DBP.0000000000000210. View

12.

Majewska M, Harrison N, Schwartz R, Barker J, Paul S . Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor. Science. 1986; 232(4753):1004-7. DOI: 10.1126/science.2422758. View

13.

Maguire J, Mody I . GABA(A)R plasticity during pregnancy: relevance to postpartum depression. Neuron. 2008; 59(2):207-13. PMC: 2875248. DOI: 10.1016/j.neuron.2008.06.019. View

14.

Mody I . GABAR Modulator for Postpartum Depression. Cell. 2019; 176(1-2):1. DOI: 10.1016/j.cell.2018.12.016. View

15.

Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A . Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet. 2017; 390(10093):480-489. DOI: 10.1016/S0140-6736(17)31264-3. View

16.

Krystal A, Pizzagalli D, Smoski M, Mathew S, Nurnberger Jr J, Lisanby S . A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. Nat Med. 2020; 26(5):760-768. PMC: 9949770. DOI: 10.1038/s41591-020-0806-7. View

17.

Bodick N, Offen W, Levey A, Cutler N, Gauthier S, Satlin A . Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997; 54(4):465-73. DOI: 10.1001/archneur.1997.00550160091022. View

18.

Shekhar A, Potter W, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C . Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry. 2008; 165(8):1033-9. DOI: 10.1176/appi.ajp.2008.06091591. View

19.

Paul S, Yohn S, Popiolek M, Miller A, Felder C . Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia. Am J Psychiatry. 2022; 179(9):611-627. DOI: 10.1176/appi.ajp.21101083. View

20.

Brannan S, Sawchak S, Miller A, Lieberman J, Paul S, Breier A . Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia. N Engl J Med. 2021; 384(8):717-726. PMC: 7610870. DOI: 10.1056/NEJMoa2017015. View